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The Challenges of Conducting
Research in Developing Countries

Sergio G. Litewka M.D., M.P.H.
University of Miami Ethics Programs
Washington University in St. Louis
November 28th 2011

Disclaimer
• The views provided in these slides are solely
the opinions of the presenter are not meant
to represent any group or organization.

Challenges of a multicultural
environment
• A working definition of research. What is
perceived by the society as research
– Production of valid, reliable, and generalizable
knowledge (Knowledge is organized information)

• Each community gives a special accent to the
activity
• Influence of the dominant paradigms

Significant Concerns
– Lack of mandatory training on research ethics and
responsible conduct of research
– Identification and management of conflicts of interest
– Enforcement of current regulations. Normative
polyphony
– Research Ethics Committees ( quorum, competence,
independence, informed consent process, logistics
and infrastructure)
– Weak or inexistent institutional accountability
– Economical disparities and access to healthcare
– Governance

Clinical Trials in Latin America
January 1st 2005- April 1st 2011
Source : Clinicaltrials.gov
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Research misconduct and Human
Subjects Protection
• Research misconduct means fabrication, falsification, or plagiarism in
proposing, performing, or reviewing research, or in reporting research
results.
(a) Fabrication is making up data or results and recording or reporting
them.
(b) Falsification is manipulating research materials, equipment, or
processes, or changing or omitting data or results such that the research is
not accurately represented in the research record.
(c) Plagiarism is the appropriation of another person's ideas, processes,
results, or words without giving appropriate credit.
(d) Research misconduct does not include honest error or differences of opinion.
• Office of Research Integrity, United States of America

Other definitions
• “All serious deviations from accepted ethical research
practices in proposing, performing and reporting research”
– Norwegian Council on Scientific Dishonesty

• “Behavior by a researcher, intentional or not that falls short
of good ethical and scientific standards”
– Joint Consensus Conference on Misconduct in Biomedical
Research . Consensus statement , Edinburgh, October 28 &
29, 1999

Research misconduct in Latin
American countries
• Magnitude and awareness of the problem
( is there a problem?)
• Perception of scientific misconduct
• Environmental factors
– Scientist, policy makers and the society
• Lack of communication between media and scientists
• Scientist may be perceived as “closed communities”

– Latin American researchers , in many cases are working for
governments ( civil servants) working within a vertical and
hierarchical system, not necessarily based in merits
– Yriart M,Braginski R. The resurrection of the crotoxine case (1989-1996):
Science, politics and media. Redes, Vol V,No 11;pp 113-139. National
University of Quilmes, Argentina

Cultural and logistical challenges in the
Latin American and Caribbean scenario
• Informed consent
– Legal information may be excessive and confusing
– Adequate disclosure of risks and eventual benefits
– Risk of therapeutic misunderstanding

• IRBs
– Definition of exempt studies
– Lack of resources
– Clinical Ethics Committees acting as Research Ethics
Committees
– Conflicts of interests- IRB independence
– Deficiencies in assuring privacy and confidentiality
– Oversight of clinical trials

Governance
Traditions and institutions by which authority in a country is exercised
– Process by which governments are selected, monitored and replaced
• Voice and accountability
• Political stability and absence of terrorism/violence
– Capacity of a government to effectively formulate and implement
sound policies
• Government effectiveness
• Regulatory quality
– Respect of the citizens and the state for the institutions that govern
interactions among them
• Rule of law
• Control of corruption
Kaufmann D, Kraay A, Mastruzzi M. Global Economy and Development.
Brookings Institutions. September 2010 www.govindicators.org

Worldwide Governance Indicators

Research misconduct in a multicultural
environment
• Understanding differences in what is
perceived as research misconduct
• Understanding that research misconduct
might be embedded in other layers of
misconduct, not necessarily linked to research
activities
• Fostering education
• Promoting transparence
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New CITI Program modules by country
( HSP and RCR)
PERU, 2

ARGENTINA, 3

MEXICO, 3
BRAZIL, 3
JAMAICA, 3

COSTA RICA, 1

COLOMBIA, 14

Conclusions: Critical issues
•
•
•
•
•

Ethical standards, laws and regulations
Post trial access to benefits
Placebo use
Local capabilities
Definition of vulnerability

